EGFR and non-small cell lung carcinoma: The high number of anticancer agents administered beyond postoperative relapse can be attributed to the wide availability of first- and subsequent-line treatment options for NSCLC, including EGFR-TKIs (gefitinib, erlotinib, afatinib, and osimertinib), platinum-based combination regimen, pemetrexed, docetaxel, S1, and immune checkpoint inhibitors (ICIs) (Table 2).